CNCE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 May 2024 @ 16:00):

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases...

Stats
Today's Volume	10.73M
Average Volume	0.00
Market Cap	401.95M
EPS	$0 ( 2023-08-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.64
ATR14	$0.231 (2.76%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-06	Van Heek Christi	Sell	25 651	Common Stock
2023-03-06	Van Heek Christi	Sell	16 400	Common Stock
2023-03-06	Van Heek Christi	Sell	25 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)
2023-03-06	Van Heek Christi	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 4 463 235

Volume Correlation

Long: 0.24 (neutral)

Short: -0.57 (weak negative)

Signal:(66.67) Neutral

Concert Pharmaceuticals Correlation

10 Most Positive Correlations
MLAI	0.815

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Concert Pharmaceuticals Correlation - Currency/Commodity

0.75
( moderate )

0.59
( weak )

-0.92
( very strong negative )

0.87
( strong )

-0.02
( neutral )

Concert Pharmaceuticals Financials

Annual	2021
Revenue:	$32 578.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2021
Revenue:	$32 578.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.00233

FY	2020
Revenue:	$7.90M
Gross Profit:	$7 902.00 (0.10 %)
EPS:	$-2.40

FY	2019
Revenue:	$1.08M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.29

Financial Reports:

No articles found.

Concert Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Concert Pharmaceuticals

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.